UNLIMITED TURBO SHORT - NOVO-NORDISK B | Real-time Boerse Frankfurt Warrants 03:50:49 30/05/2024 pm IST | ||
| 3.67 EUR | -4.68% |
|
| Current month | -1.53% | ||
| 1 month | -7.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 30/24/30 | 3.67 | -4.68% |
| 29/24/29 | 3.85 | +1.58% |
| 28/24/28 | 3.79 | +2.43% |
| 27/24/27 | 3.7 | +3.06% |
| 24/24/24 | 3.59 | +2.87% |
Real-time Boerse Frankfurt Warrants
Last update May 30, 2024 at 03:50 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PC40NC |
| ISIN | DE000PC40NC4 |
| Date issued | 12/02/2024 |
| Strike | 1,193 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.26 € |
|---|---|
| Lowest since issue | 3.44 € |
| Spread | 0.01 € |
| Spread % | 0.27% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
911.5
DKK
Average target price
917.2
DKK
Spread / Average Target
+0.63%
- Stock Market
- Certificates
- Certificat
